304 related articles for article (PubMed ID: 17952653)
1. Cannabinoids and neuroprotection in basal ganglia disorders.
Sagredo O; García-Arencibia M; de Lago E; Finetti S; Decio A; Fernández-Ruiz J
Mol Neurobiol; 2007 Aug; 36(1):82-91. PubMed ID: 17952653
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic potential of cannabinoids as neuroprotective agents for damaged cells conducing to movement disorders.
Antonazzo M; Botta M; Bengoetxea H; Ruiz-Ortega JÁ; Morera-Herreras T
Int Rev Neurobiol; 2019; 146():229-257. PubMed ID: 31349929
[TBL] [Abstract][Full Text] [Related]
3. Cannabinoids and neuroprotection in motor-related disorders.
de Lago E; Fernández-Ruiz J
CNS Neurol Disord Drug Targets; 2007 Dec; 6(6):377-87. PubMed ID: 18220777
[TBL] [Abstract][Full Text] [Related]
4. Recent Advances in the Potential of Cannabinoids for Neuroprotection in Alzheimer's, Parkinson's, and Huntington's Diseases.
Pérez-Olives C; Rivas-Santisteban R; Lillo J; Navarro G; Franco R
Adv Exp Med Biol; 2021; 1264():81-92. PubMed ID: 33332005
[TBL] [Abstract][Full Text] [Related]
5. The endocannabinoid system as a target for the treatment of motor dysfunction.
Fernández-Ruiz J
Br J Pharmacol; 2009 Apr; 156(7):1029-40. PubMed ID: 19220290
[TBL] [Abstract][Full Text] [Related]
6. Cannabinoids and Parkinson's disease.
García-Arencibia M; García C; Fernández-Ruiz J
CNS Neurol Disord Drug Targets; 2009 Dec; 8(6):432-9. PubMed ID: 19839934
[TBL] [Abstract][Full Text] [Related]
7. Prospects for cannabinoid therapies in basal ganglia disorders.
Fernández-Ruiz J; Moreno-Martet M; Rodríguez-Cueto C; Palomo-Garo C; Gómez-Cañas M; Valdeolivas S; Guaza C; Romero J; Guzmán M; Mechoulam R; Ramos JA
Br J Pharmacol; 2011 Aug; 163(7):1365-78. PubMed ID: 21545415
[TBL] [Abstract][Full Text] [Related]
8. Endocannabinoids and Neurodegenerative Disorders: Parkinson's Disease, Huntington's Chorea, Alzheimer's Disease, and Others.
Fernández-Ruiz J; Romero J; Ramos JA
Handb Exp Pharmacol; 2015; 231():233-59. PubMed ID: 26408163
[TBL] [Abstract][Full Text] [Related]
9. Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease.
Lastres-Becker I; Molina-Holgado F; Ramos JA; Mechoulam R; Fernández-Ruiz J
Neurobiol Dis; 2005; 19(1-2):96-107. PubMed ID: 15837565
[TBL] [Abstract][Full Text] [Related]
10. Potential role of cannabinoids in Parkinson's disease.
Sevcík J; Masek K
Drugs Aging; 2000 Jun; 16(6):391-5. PubMed ID: 10939305
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's disease: importance of antioxidant and cannabinoid receptor-independent properties.
García-Arencibia M; González S; de Lago E; Ramos JA; Mechoulam R; Fernández-Ruiz J
Brain Res; 2007 Feb; 1134(1):162-70. PubMed ID: 17196181
[TBL] [Abstract][Full Text] [Related]
12. Neuroprotective strategies for basal ganglia degeneration: Parkinson's and Huntington's diseases.
Alexi T; Borlongan CV; Faull RL; Williams CE; Clark RG; Gluckman PD; Hughes PE
Prog Neurobiol; 2000 Apr; 60(5):409-70. PubMed ID: 10697073
[TBL] [Abstract][Full Text] [Related]
13. Cannabinoid pharmacology/therapeutics in chronic degenerative disorders affecting the central nervous system.
Aymerich MS; Aso E; Abellanas MA; Tolon RM; Ramos JA; Ferrer I; Romero J; Fernández-Ruiz J
Biochem Pharmacol; 2018 Nov; 157():67-84. PubMed ID: 30121249
[TBL] [Abstract][Full Text] [Related]
14. The therapeutic potential of the cannabinoids in neuroprotection.
Grundy RI
Expert Opin Investig Drugs; 2002 Oct; 11(10):1365-74. PubMed ID: 12387700
[TBL] [Abstract][Full Text] [Related]
15. The endocannabinoid system as a target for the treatment of neuronal damage.
Fernández-Ruiz J; García C; Sagredo O; Gómez-Ruiz M; de Lago E
Expert Opin Ther Targets; 2010 Apr; 14(4):387-404. PubMed ID: 20230193
[TBL] [Abstract][Full Text] [Related]
16. Promising cannabinoid-based therapies for Parkinson's disease: motor symptoms to neuroprotection.
More SV; Choi DK
Mol Neurodegener; 2015 Apr; 10():17. PubMed ID: 25888232
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic Molecular Insights into the Active Engagement of Cannabinoids in the Therapy of Parkinson's Disease: A Novel and Futuristic Approach.
Jain V; Behl T; Sehgal A; Singh S; Sharma N; Makeen HA; Albratty M; Meraya AM; Najmi A
Neurotox Res; 2023 Feb; 41(1):85-102. PubMed ID: 36567416
[TBL] [Abstract][Full Text] [Related]
18. Benefits of VCE-003.2, a cannabigerol quinone derivative, against inflammation-driven neuronal deterioration in experimental Parkinson's disease: possible involvement of different binding sites at the PPARγ receptor.
García C; Gómez-Cañas M; Burgaz S; Palomares B; Gómez-Gálvez Y; Palomo-Garo C; Campo S; Ferrer-Hernández J; Pavicic C; Navarrete C; Luz Bellido M; García-Arencibia M; Ruth Pazos M; Muñoz E; Fernández-Ruiz J
J Neuroinflammation; 2018 Jan; 15(1):19. PubMed ID: 29338785
[TBL] [Abstract][Full Text] [Related]
19. Cannabinoid control of motor function at the basal ganglia.
Fernández-Ruiz J; Gonzáles S
Handb Exp Pharmacol; 2005; (168):479-507. PubMed ID: 16596785
[TBL] [Abstract][Full Text] [Related]
20. Role of CB2 receptors in neuroprotective effects of cannabinoids.
Fernández-Ruiz J; Pazos MR; García-Arencibia M; Sagredo O; Ramos JA
Mol Cell Endocrinol; 2008 Apr; 286(1-2 Suppl 1):S91-6. PubMed ID: 18291574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
